Skip to main content
    M

    Mirum Pharmaceuticals Inc (MIRM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $91.58
    -2.41 (-2.56%)

    Market Cap: $6.14B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Mirum Pharmaceuticals Inc (MIRM) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Mirum Pharmaceuticals reported revenue of $521.31M for the fiscal year ended Dec 31, 2025, up 54.7% from the year before. That year, net income was -$23.36M with a net margin of -4.5%, operating cash flow was $55.83M and free cash flow was $54.87M. The quarter ended Sep 30, 2026 had revenue of $185.72M and net income of -$40.77M.

    Revenue and Margins

    The operating margin was -4.2% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$521.31M+54.7%80.8%-4.2%-4.5%
    Dec 2024$336.89M+80.8%75.8%-26.0%-26.1%
    Dec 2023$186.37M+141.8%74.8%-58.6%-87.7%
    Dec 2022$77.06M+302.7%83.9%-170.3%-176.0%
    Dec 2021$19.14MN/A100.0%-906.1%-438.9%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$521.31M$336.89M$186.37M$77.06M$19.14M$0$0$0
    Cost of revenue$100.24M$81.64M$47.04M$12.37M$0$0$0$0
    Gross profit$421.07M$255.25M$139.34M$64.69M$19.14M$0$0$0
    Research and development$186.18M$140.63M$102.61M$106.84M$131.43M$81.61M$42.99M$2.33M
    Operating income-$22.14M-$87.61M-$109.15M-$131.22M-$173.41M-$104.30M-$54.74M-$2.92M
    Net income-$23.36M-$87.94M-$163.41M-$135.66M-$83.99M-$103.27M-$52.55M-$17.35M
    EBITDA$6.22M-$61.10M-$100.03M-$127.08M-$66.27M-$103.94MN/AN/A
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$185.72M$176.24M$159.88M$148.93M$133.01M$127.78M$111.58M$99.41M$90.38M$77.88M$69.22M$69.55M
    Gross profit$150.55M$145.90M$131.08M$120.67M$107.47M$104.36M$88.57M$76.63M$69.57M$57.65M$51.39M$44.53M
    Operating income-$59.75M-$42.54M-$789.47M-$4.57M$2.60M-$4.99M-$15.18M-$24.22M-$12.68M-$24.23M-$26.47M-$32.59M
    Net income-$40.77M-$67.23M-$790.15M-$5.73M$2.90M-$5.86M-$14.68M-$23.79M-$14.23M-$24.64M-$25.28M-$35.66M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $311.94M exceeded cash and equivalents by $15.25M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$842.81M$670.75M$646.62M$352.91M$294.65M$240.86M$146.71M$51.98M
    Current assets$549.68M$392.79M$387.54M$190.22M$166.59M$236.35M$119.36M$51.98M
    Cash and equivalents$296.68M$222.50M$286.33M$28.00M$31.34M$142.09M$11.97M$51.96M
    Total liabilities$528.12M$445.11M$397.95M$210.87M$174.44M$68.77M$16.36M$2.45M
    Short-term debt$2.14M$1.71M$1.10M$931.00K$711.00K$636.00K$397.00K$0
    Long-term debt$309.80M$308.08M$306.42M$0N/AN/AN/A$0
    Shareholder equity$314.69M$225.64M$248.67M$142.04M$120.21M$172.09M$130.35M-$17.31M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.03B$1.04B$890.92M$842.81M$785.12M$725.83M$690.25M$670.75M$667.89M$660.75M$651.96M$646.62M
    Total liabilities$1.08B$1.06B$648.42M$528.12M$493.07M$470.67M$456.99M$445.11M$435.87M$431.77M$417.36M$397.95M
    Cash and equivalents$243.19M$330.73M$324.91M$296.68M$282.02M$228.12M$211.82M$222.50M$222.97M$233.25M$302.84M$286.33M
    Shareholder equity-$54.19M-$10.42M$242.49M$314.69M$292.05M$255.16M$233.26M$225.64M$232.02M$228.99M$234.60M$248.67M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.3% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow$55.83M$10.32M-$70.94M-$120.14M-$132.76M-$89.08M-$39.36M-$373.00K
    Capital expenditures$954.00K$993.00K$109.00K$278.00K$24.00K$225.00K$281.00K$7.50M
    Free cash flow$54.87M$9.33M-$71.05M-$120.41M-$132.78M-$89.30M-$39.64M-$7.87M
    Dividends paidN/AN/AN/A$5.55M$0N/AN/A$0
    Share repurchases$0$0$281.00K$0$0N/A$0N/A
    Investing cash flow-$23.95M-$90.13M-$107.20M$7.70M$48.55M$37.87M-$127.78M-$7.50M
    Financing cash flow$40.14M$17.70M$336.60M$109.09M$73.47M$181.29M$127.18M$59.84M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.31M-$44.25M-$228.76M$6.07M$39.68M$12.04M-$1.96M-$5.07M$3.98M-$3.80M$15.21M-$16.62M
    Capital expenditures$1.30M$23.00K$664.00K$600.00K$187.00K$126.00K$41.00K$20.00K$181.00K$779.00K$13.00K$5.00M
    Free cash flow-$5.62M-$44.27M-$229.43M$5.47M$39.49M$11.91M-$2.00M-$5.09M$3.80M-$4.58M$15.20M-$21.62M
    Last 12 quarters

    Frequently Asked Questions About MIRM

    What is Mirum Pharmaceuticals' annual revenue?

    Mirum Pharmaceuticals reported revenue of $521.31M for the fiscal year ended Dec 31, 2025.

    How fast is Mirum Pharmaceuticals' revenue growing?

    Revenue was up 54.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 89.1%.

    Is Mirum Pharmaceuticals profitable?

    No. Mirum Pharmaceuticals reported net income of -$23.36M for the fiscal year ended Dec 31, 2025, with a net margin of -4.5%.

    How much free cash flow does MIRM generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $55.83M minus capital expenditures of $954.00K produced free cash flow of $54.87M.

    How much debt does Mirum Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $309.80M, short-term debt of $2.14M and cash and equivalents of $296.68M.